<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Martorell, Claudia</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Switching from RTV to COBI is Feasible in Patients with HIV-1 Who Have Mild-to-Moderate Renal Impairment</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Cobicistat (COBI; approved as Tybost™ in the European Union and under review in the United States) is well tolerated in HIV-1 patients with mild-to-moderate renal impairment. The latest results build on prior phase 3 data demonstrating the long-term (144-week) noninferiority of COBI—which is eliminated mainly by liver metabolism, negating the need for dose adjustment in renal-impaired patients—to ritonavir as a protease inhibitor booster in treatment of HIV-1 infection in treatment-naïve patients.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>